Groupon, Spectrum Brands, Adobe And Other Big Losers From Thursday
U.S. stocks closed lower with the Nasdaq 100 dropping around 200 points on Thursday. Here is the list of some big stocks recording losses in the previous session.
Jim Cramer On Energy: ‘These Stocks Are So Cheap, You Can Trade Them For A Bounce’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he does not want to recommend Sunnova Energy International Inc. (NYSE: NOVA) at these prices, with the company also losing money.
10 Energy Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
German Government Sees Problem With Coal Supply For Power Plants, Oil Supply In Eastern Areas In Autumn, Winter
-Reuters Citing Economy Ministry Document
Dow Dips 450 Points; Crude Oil Falls Sharply
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 450 points on Monday.
BJ’s Wholesale Club, Cisco, Canadian Solar And Some Other Big Stocks Recording Gains On Thursday
U.S. stocks closed mostly higher on Thursday. Here is the list of some big stocks moving higher in the previous session.
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.
‘The Bigger The Base, The Higher The Space’: Analyst Sees 45% Upside Potential On This Mining Play
The Energy Select Sector SPDR Fund (NYSE: XLE) was up 34.45% year-to-date, alongside major energy names such as Exxon Mobil Corp (NYSE: XOM) and Chevron Corporation (NYSE:
Qualys, ShockWave Medical, News Corporation And Some Other Big Stocks Moving Higher On Tuesday
Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.